WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial milestones to be determined at a future date, which could include revenue and earnings targets. Any consideration of a special dividend would be subject to the Company’s future fin ...

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including revenue. The ...

Core Insights - Tevogen Bio Holdings Inc. reported significant scientific and operational milestones in 2025, focusing on scalable cell therapy development [1][5] Group 1: Platform Development - Tevogen advanced its proprietary ExacTcell™ platform, enhancing laboratory yields of target-specific cytotoxic T lymphocytes (CTLs) to improve consistency and throughput [2][3] - The improvements in the ExacTcell™ platform are aimed at enabling efficient clinical supply and supporting future clinical and commercial manufacturing across multiple programs [3] Group 2: Pipeline Expansion - Tevogen completed T cell target identification for five additional HLA restrictions, significantly expanding potential patient coverage for its SARS-CoV-2-specific CTL product [4] - The company advanced target discovery and preclinical activities for CTL therapies, supported by its advanced analytics division, Tevogen.AI, which aids in peptide target identification and prioritization [4][9] Group 3: Strategic Positioning - The CEO of Tevogen emphasized that 2025 was a defining year, highlighting the establishment of a scalable CTL platform and the foundation for manufacturing necessary for clinical and commercial outcomes [5] - Tevogen is exploring future strategic initiatives, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, to broaden patient access and advance sustainable innovation [10]

Core Viewpoint - Tevogen Bio Holdings Inc. has made a significant charitable contribution of 230,000 shares to support underserved communities through a recognized nonprofit organization [2][3] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [4] - The company aims to develop advanced therapies across various therapeutic areas and enhance the healthcare system's scalability [4] Clinical Development - Tevogen Bio has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, indicating potential in treating various diseases [5] - The pipeline includes programs in virology, oncology, and neurology, leveraging the proprietary ExacTcell™ platform [5] Technological Innovation - Tevogen.AI is designed to enhance drug development by improving target detection and clinical trial design through predictive technologies [6] - The platform collaborates with major technology providers like Microsoft and Databricks to facilitate rapid therapeutic discovery [6] Strategic Initiatives - The company is exploring future initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions to broaden patient access [7] - These initiatives align with Tevogen's mission to promote sustainable innovation and create a more equitable healthcare model [7]

Core Viewpoint - Tevogen Bio Holdings Inc. demonstrates its commitment to community support through a significant donation of 50,000 shares by its Founder and CEO, Dr. Ryan Saadi, to the Mt. Bethel Fire Company, reflecting the company's dedication to local first responders and the Warren Township community [2][3][4]. Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing advanced artificial intelligence and precision T cell therapy platforms to develop life-saving therapies [5]. - The company has an estimated asset valuation of $10 billion and a secured cash runway for commercialization, indicating strong financial health and growth potential [4]. Clinical and Technological Advancements - Tevogen Bio has completed a proof-of-concept clinical trial for its single-HLA–restricted, genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [6]. - The Tevogen.AI platform aims to transform drug development by enhancing target detection and optimizing clinical trial design, utilizing cloud and data services from major technology providers [7][8]. Strategic Initiatives - Tevogen is exploring future initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [9].

Core Viewpoint - Tevogen Bio Holdings Inc. has made a significant contribution to the Warren Township Honorary Policemen's Benevolent Association, with its Founder and CEO, Dr. Ryan Saadi, donating 230,000 shares of common stock to support local community initiatives [2][3][4]. Group 1: Donation Impact - The donation will be utilized to acquire critical equipment that enhances the safety of police officers and residents, thereby strengthening community services [6][7]. - The contribution reflects a commitment to community welfare and acknowledges the importance of law enforcement in maintaining safety [5][8]. Group 2: Company Overview - Tevogen is recognized for its disciplined execution and has a significant multi-billion-dollar potential in its long-term vision, emphasizing responsibility towards the communities it serves [9]. - The company operates as a next-generation healthcare enterprise, focusing on affordability, efficiency, and scientific rigor, leveraging advanced technologies for developing life-saving therapies [11]. Group 3: Research and Development - Tevogen Bio has completed a proof-of-concept clinical trial for its T cell therapy, with a pipeline that spans virology, oncology, and neurology [12]. - The company is also developing Tevogen.AI, a platform aimed at transforming drug development through advanced predictive technologies [13]. Group 4: Future Initiatives - Tevogen is exploring strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation in healthcare [14].

Core Points - Tevogen Bio Holdings Inc. announced a significant donation of 230,000 shares from its Founder and CEO, Dr. Ryan Saadi, to the Warren Township Honorary Policemen's Benevolent Association [2][10] - The donation aims to support local community initiatives, including safety equipment for police officers and community welfare programs [3][6] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing advanced technologies for developing life-saving therapies [11] - The company has a diverse pipeline that includes programs in virology, oncology, and neurology, leveraging its proprietary ExacTcell™ platform [12] Community Engagement - The donation reflects Tevogen's commitment to community responsibility and enhancing the safety of local law enforcement [9][8] - The funds will be allocated for critical equipment to improve the safety and effectiveness of police services in Warren Township [6][7]

Core Insights - Tevogen Bio Holdings Inc. recognizes Dr. Curtis Patton for his significant contributions to the field of medicine and the company, particularly in advancing its ExacTcell™ precision T cell platform and achieving revenue forecasts exceeding $1 billion [3][4]. Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms to develop life-saving therapies [6]. - The company has completed a proof-of-concept clinical trial for its allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [7]. Technological Advancements - Tevogen.AI aims to transform drug development by enhancing target detection and optimizing clinical trial design through proprietary predictive technologies, utilizing cloud services from major tech providers [8]. Strategic Initiatives - The company is exploring future initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [9].

Core Insights - Tevogen Bio Holdings Inc. has been recognized in the 2025 New Jersey Power List by NJBIZ for its influence on the state's economic and innovation landscape [1][2] Company Overview - Tevogen is a next-generation healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [4] - The company is committed to advancing life-saving therapies across various therapeutic areas and aims to broaden patient access through innovative healthcare solutions [7] Technological Advancements - The ExacTcell™ platform is a key innovation, with a pipeline addressing infectious diseases, oncology, and neurology [2][5] - Tevogen.AI technology is designed to enhance drug development by improving target detection and clinical trial design, leveraging cloud services from major tech providers [6] Financial Projections - Tevogen anticipates approximately $1 billion in first-year specialty-care revenue and a cumulative five-year revenue forecast of $18–22 billion [2] Expansion and Commitment - The company is expanding its operations with a new 17,428-square-foot manufacturing facility and headquarters, which will centralize R&D and regulatory functions [3]

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes its commitment to capital-efficient operations and sustainable practices in the biotechnology industry, as highlighted in its quarterly report for Q3 2025 [1][8]. Financial Performance - The company reported a loss from operations of $5.7 million for Q3 2025, a 6% decrease compared to Q3 2024 [2][3]. - For the nine months ended September 30, 2025, the operating loss was $21.5 million, reflecting a 51% reduction compared to the same period in 2024 [2][3]. - Total operating expenses for Q3 2025 were $5.7 million, down from $6.1 million in Q3 2024 [3]. - Research and development expenses for Q3 2025 were $3.1 million, compared to $3.3 million in Q3 2024 [3]. - General and administrative expenses decreased to $2.6 million in Q3 2025 from $2.8 million in Q3 2024 [3]. Non-GAAP Financial Metrics - On a non-GAAP basis, the adjusted loss from operations was $2.5 million for Q3 2025, a 10% reduction from $2.8 million in Q3 2024 [5][6]. - For the nine months ended September 30, 2025, the adjusted loss from operations was $7.8 million, a 25% decrease from $10.4 million in the same period of 2024 [5][7]. Strategic Focus - The company aims to transition from traditional high-cost drug development to a more efficient model that emphasizes patient affordability while maintaining profitability [8]. - Tevogen is committed to scalable science and responsible execution, focusing on broad patient access in its pipeline for infectious diseases and oncology [8].